The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin ...
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare ...
US-based biotechnology company Seattle Genetics has announced that it has gained the Health Canada's Notice of Compliance with conditions (NOC/c) for marketing its ADCETRIS ((Brentuximab Vedotin)) drug used in treating two lymphoma ...
Tags: Seattle Genetics, ADCETRIS drug, Health Canada's Notice of Compliance
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional approval for Takeda Pharmaceuticals and Millennium adcetris (brentuximab vedotin) in Europe. If the CHMP ...
Tags: CHMP, refractory CD30 positive Hodgkin lymphoma, sALCL
Takeda Pharmaceutical Company and Millennium: The Takeda Oncology Company have won European conditional marketing authorization for Adcetris (brentuximab vedotin). Adcetris is indicated for use in adult patients with relapsed or ...
Tags: adcetris, antibody-drug conjugate, Brentuximab vedotin, sALCL